Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | USP14 | P54578 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2343158 | 0.90 | KDM4E (0.52) | NPSR1MAPTSMN1; SMN2HTTNOD2 | |
| SCHEMBL29954953 | 0.90 | KDM4E (0.52) | NPSR1MAPTSMN1; SMN2HTTNOD2 | |
| SCHEMBL2345076 | 0.88 | HTT (0.38) | NPSR1MAPTSMN1; SMN2HTTNOD2 | |
| SCHEMBL2341924 | 0.88 | ALDH1A1 (0.48) | NPSR1MAPTSMN1; SMN2HTTNOD2 | |
| SCHEMBL2347546 | 0.88 | LMNA (0.47) | NPSR1MAPTSMN1; SMN2HTTNOD2 | |
| SCHEMBL2348488 | 0.88 | MAPT (0.48) | NPSR1MAPTSMN1; SMN2HTTNOD2 | |
| SCHEMBL2346039 | 0.88 | LMNA (0.50) | NPSR1MAPTSMN1; SMN2HTTNOD2 | |
| SCHEMBL2349756 | 0.85 | LMNA (0.50) | NPSR1MAPTSMN1; SMN2HTTNOD2 | |
| SCHEMBL2345291 | 0.84 | NPSR1 (0.44) | NPSR1MAPTSMN1; SMN2HTTNOD2 | |
| SCHEMBL18235059 | 0.84 | NPSR1 (0.50) | NPSR1MAPTSMN1; SMN2HTTNOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958873-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20220298181-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11242361-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-20180282352-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2018-10-04 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| WO-2015073528-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073528-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-8008491-B2 | poly(adenosine 5'-diphosphate ribose) polymerase inhibitors such as 1-phenyl-2-(piperazin-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridine-3-carboxaldehyde, used in the treatment and/or prevention central nervous system and cardiovascular disorders | AVENTIS PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2008-10-16 | — | — | US | disclosed |
| CN-1870991-A | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMA INC (US) | 2006-11-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NPSR1 4146/4885MAPT 943/4885SMN1; SMN2 532/4885 |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NPSR1 4146/4885MAPT 943/4885SMN1; SMN2 532/4885 |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP11, PARP15 | NPSR1 650/4885MAPT 3033/4885SMN1; SMN2 2288/4885 |
| US-20180282352-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NPSR1 4146/4885MAPT 943/4885SMN1; SMN2 532/4885 |
| US-20220298181-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NPSR1 4146/4885MAPT 943/4885SMN1; SMN2 532/4885 |
| US-11242361-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | NPSR1 4146/4885MAPT 943/4885SMN1; SMN2 532/4885 |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NPSR1 4146/4885MAPT 943/4885SMN1; SMN2 532/4885 |
| US-11958873-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | NPSR1 4146/4885MAPT 943/4885SMN1; SMN2 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.